Melatonin Is Not Just a Sleep Pill: Your Nightly Dose Is Quietly Reshaping Your Metabolic and Inflammatory Biomarkers

The surprising part about melatonin is this: it is not just for sleep. Many people never check blood tests. So they miss changes in liver, sugar, and inflammation.

This means your nightly pill may shift your labs. Your ALT may drop. Your fasting glucose may drop too. But your triglycerides may rise in some cases. You cannot feel these changes.

Start low and use clear numbers. Try 0.5–1 mg first, 30–60 minutes before bed. If needed, try 3 mg, and do not exceed 5 mg without advice. Get labs before you start and again at 8–12 weeks. Track ALT, fasting glucose, and triglycerides.

When most people take melatonin, they think only about sleep. But your dose can also shift blood markers tied to liver health, blood sugar, and inflammation. The strongest overview is a 2025 meta-analysis of 63 randomized controlled trials (RCTs) that tracked many cardiometabolic labs [1].

In that analysis, melatonin lowered ALT (a liver enzyme) by 2.61 IU/L on average (95% CI: -4.87 to -0.34) [1]. In people with fatty liver disease, another meta-analysis found ALT also dropped after 4 weeks of use [2]. These are lab changes you will not “feel.”

The same 2025 meta-analysis also found small average improvements in some lipid markers, including total cholesterol [1]. But not every marker moves the same way in every person. That is why sleep success alone is not a full safety check.

Melatonin also shows measurable antioxidant effects in human trials. A 2024 meta-analysis of 14 RCTs (823 people) found melatonin increased glutathione, with an SMD of 0.66 (95% CI: 0.28 to 1.03; P = 0.001) [3].

Glutathione helps protect cells from oxidative stress. It also supports normal detox pathways in the liver. Few supplements show repeat lab gains in glutathione across trials.

Other meta-analyses also report increases in antioxidant enzymes such as glutathione peroxidase (P < 0.001) [4]. Most people will never see these shifts unless they run specific tests.

While melatonin's effects on liver enzymes and antioxidant systems are remarkably consistent, its impact on lipid metabolism reveals a more complex picture that highlights the importance of individual monitoring. Some studies show triglyceride levels decreasing with melatonin supplementation, while others document increases, creating a bidirectional effect that population averages can mask.

This variability suggests that melatonin's metabolic effects may depend on individual factors like baseline health status, genetic variations in melatonin metabolism, or concurrent medications and supplements. The same 3-5 mg dose that improves inflammatory markers in one person might simultaneously worsen lipid profiles in another, making personal biomarker tracking essential for determining net benefit.

The triglyceride paradox exemplifies a broader principle in personalized supplementation: population-level research can identify average effects, but individual responses often vary significantly from these averages. This is particularly relevant for melatonin because its metabolic effects are "silent"—they don't produce noticeable symptoms the way sleep improvements do. Without regular lipid panels, users have no way to know whether their melatonin regimen is providing metabolic benefits or creating biochemical changes that could impact cardiovascular health over time.

Dose matters, and more is not always better. Many sleep studies find benefits level off at modest doses, not very high ones [6]. For metabolic labs, many RCTs use similar bedtime dosing, but ideal “lab-optimized” dosing is not settled.

A practical plan is to start with 0.5–1 mg, taken 30–60 minutes before bed. If sleep is still poor, you can try 3 mg. Many people stop at 5 mg to avoid next-day grogginess. Higher doses may raise side effects without clear added benefit.

Timing matters too. Taking it too early may shift your body clock. Taking it too late may blunt the sleep effect. Pick one time and keep it steady while you track results.

If you use melatonin often, biomarker tracking is the missing step. Sleep is a feeling. Lab changes are silent.

Start with baseline labs before you begin. Recheck after 8–12 weeks on the same dose and timing. This window is long enough to see trends, and short enough to catch problems early.

Focus on a short list first: ALT, fasting glucose (and HbA1c if you can), and a full lipid panel with triglycerides. If your clinician offers them, hs-CRP and IL-6 can add more detail. Use the results to decide if melatonin is a net win for your body, not just your bedtime.

Melatonin is a sleep aid, but it is also a hormone with body-wide effects. In meta-analyses, it can lower ALT and raise antioxidant markers like glutathione. Some cardiometabolic markers improve on average, but your own response can differ.

If you want the benefits and fewer surprises, use a simple plan. Take 0.5–3 mg 30–60 minutes before bed, and avoid chasing very high doses. Then confirm the effect with labs like ALT, fasting glucose, and triglycerides after 8–12 weeks.